X

Drug Profile

Idebenone - Takeda

Alternative Names: Avan; Cerestabon; CV 2619; Daruma; Mnesis

Latest Information Update: 23 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Developer Pfizer; Seber; Takeda
Class Benzoquinones; Coenzymes; Eye disorder therapies; Neuroprotectants; Nootropics; Small molecules
Mechanism of Action Antioxidants; Free radical scavengers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Alzheimer's disease
No development reported Cognition disorders

Most Recent Events

16 Oct 2009 Wyeth has been acquired by Pfizer
23 Dec 2003 A study has been added to the Alzheimer's disease therapeutic trials section
25 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are now called Wyeth

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com